Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine vs placebo for ADHD symptoms in children and adolescents with autism spectrum disorder
2006-000304-16Phase 4
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) and Autism Spectrum Disorder (ASD) comparing Atomoxetine with Placebo (2 arms). Primary endpoint: ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2006-000304-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000304-16.